Using technology from Purdue University, Moerae Matrix is advancing a suite of peptide therapeutics that specifically target MAPKAP kinase 2 (MK2) in the TGF-beta/p38 pathway. Their lead candidate, MMI-0100, has shown promising anti-fibrotic activity in multiple models of fibrosis, including pulmonary fibrosis. The company is also developing a pulmonary delivery formulation of MMI-0100 for chronic treatment of idiopathic pulmonary fibrosis (IPF). Moerae Matrix's pipeline includes other MK2 inhibitor candidates for diseases where MK2 dysregulation may be involved. Additionally, the company operates a platform of formulation and delivery technologies to enhance the efficacy of their proprietary programs.